Lipid-lowering effect of berberine in human subjects and rats

Hu, Yueshan; Ehli, Erik A.; Kittelsrud, Julie M.; Ronan, Patrick J.; Munger, Karen A.; Downey, Terry; Bohlen, Krista; Callahan, Leah; Munson, Vicki; Jahnke, Mike; Marshall, Lindsey L.; Nelson, Kelly P.; Huizenga, Patricia; Hansen, Ryan J.; Soundy, Timothy J.; Davies, Gareth E.

doi:10.1016/j.phymed.2012.05.009

Cited by 118 publications

(79 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, berberine, a constituent of AP tablets, has been described as having produced a mild weight loss in obese human subjects [21]. The overall benefit of AP appears to be an improvement in CVD risk in populations with hyperlypidemia and medium-high CVD risk [12], [22]-[25].…”

Section: Introductionmentioning

confidence: 99%

Effects of Poly-Bioactive Compounds on Lipid Profile and Body Weight in a Moderately Hypercholesterolemic Population with Low Cardiovascular Disease Risk: A Multicenter Randomized Trial

et al. 2014

View full text Add to dashboard Cite

A dietary supplement (AP, Armolipid Plus) that combines red yeast rice extract, policosanol, berberine, folic acid, coenzyme Q10 and asthaxantine can have beneficial effects on cardiovascular disease (CVD) biomarkers. The aim of this study was to assess whether the intake of AP, in combination with dietary recommendations, reduces serum low density lipoprotein cholesterol (LDL-c) concentrations and other CVD biomarkers in patients with hypercholesterolemia. Eligible patients were recruited from the outpatient clinics of six Spanish hospitals Hospital Virgen del Rocío (Sevilla); Hospital San Jorge (Huesca); Hospital San Pedro (Logroño); Hospital Gregorio Marañón (Madrid), Hospital la Fe (Valencia) and Hospital Universitari Sant Joan (Reus) as recruiting and coordinating center. 102 participants (mean age ± SD; 50.91±11.61; 32 men) with low CVD, with mild-to-moderately elevated LDL-c (between 3.35 mmol/L and 4.88 mmol/L) without hypolipemic therapy were randomized in a double-blind, parallel, controlled, multicenter trial commencing January 2012 and ending December 2012. Among the exclusion criteria were any concomitant chronic disease, triglycerides (TG) >3.97 mmol/L, pregnant or lactating, and history of CVD. At 12 weeks, compared to placebo, AP reduced LDL-c by −6.9%, apolipoprotein (Apo) B-100 by −6.6% and total cholesterol/HDL-c ratio by −5.5%, the ApoB/ApoA1 ratio by −8.6%, while increasing ApoA1 by +2.5% (p<0.05). AP consumption was associated with modest mean weight loss of −0.93 kg (95%CI: -1.74 to -0.12; P = 0.02) compared with control group while dietary composition remained unchanged in the AP group. The AP product was well tolerated. In conclusion, AP, combined with dietary recommendations, reduced LDL-c levels as well as total cholesterol/HDL-c and ApoB/ApoA1 ratios, while increasing Apo A1, all of which are improvements in CVD risk indicators. AP is a product which could benefit patients having moderate hyperlipidemia and excess body weight.Trial RegistrationClinicalTrials.gov NCT01562080

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Poly-Bioactive Compounds on Lipid Profile and Body Weight in a Moderately Hypercholesterolemic Population with Low Cardiovascular Disease Risk: A Multicenter Randomized Trial

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Oral administration of berberine (0.5 g twice/day, 3 months) for the hypercholesterolemic Chinese patients resulted in significant decline in serum levels of cholesterol, TG, and LDL-C but no change in HDL-C compared to placebo groups [66]. This was also replicated by another study in human subjects with a mild weight loss (average 5 lb/subject) and in SD rats [67]. The mechanism was explained by the upregulation of LDLR by berberine in the test of human hepatoma cells and the treatment of hyperlipidemic hamsters [66].…”

Section: Studies Of Single Herbsmentioning

confidence: 80%

“…Human subjects had no side effects observed and were well tolerated with the dosage of berberine [66, 67] or combined with simvastatin [68] so reduction of statin dosage in clinic by adding berberine may be possible.…”

Section: Studies Of Single Herbsmentioning

confidence: 99%

A Review on the Traditional Chinese Medicinal Herbs and Formulae with Hypolipidemic Effect

Sham

Chan

Wang

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Hyperlipidemia, characterized by the abnormal blood lipid profiles, is one of the dominant factors of many chronic diseases such as diabetes, obesity, and cardiovascular diseases (CVD). For the low cost, effectiveness, and fewer side effects, the popularity of using traditional Chinese medicine (TCM) to handle hyperlipidemia is increasing and its role in health care has been recognized by the public at large. Despite the importance of TCM herbs and formulations, there is no comprehensive review summarizing their scientific findings on handling hyperlipidemia. This review summarizes the recent experimental and clinical results of nine representative single Chinese herbs and seven classic TCM formulae that could improve lipid profiles so as to help understand and compare their underlying mechanisms. Most of single herbs and formulae demonstrated the improvement of hyperlipidemic conditions with multiple and diverse mechanisms of actions similar to conventional Western drugs in spite of their mild side effects. Due to increasing popularity of TCM, more extensive, well-designed preclinical and clinical trials on the potential synergistic and adverse side effects of herb-drug interactions as well as their mechanisms are warranted. Hyperlipidemic patients should be warned about the potential risks of herb-drug interactions, particularly those taking anticoagulants and antiplatelet drugs.

show abstract

“…In two small studies, obese subjects taking 1.5 g/day of berberine hydrochloride had a nonsignificant 12 % reduction in total cholesterol; while patients with type 2 diabetes had a significant 13 % decrease in total cholesterol after 3 months [127,128]. More convincingly, a randomized controlled trial of 144 hypercholesterolemic Caucasian subjects showed that consuming 500 mg of berberine twice daily significantly decreased total cholesterol, LDL-cholesterol, and triglycerides by 11.6, 16.4 and 21.2 %, respectively, and increased HDL cholesterol by 9.1 % [129].…”

Section: Berberinementioning

confidence: 98%

“…The most commonly reported adverse reactions to berberine are gastrointestinal in nature, consisting of self-limiting constipation, flatulence; and in rare instances headache [122,127,129,131]. Berberine appears to be safe for use in patients with chronic liver disease, including chronic hepatitis B, hepatitis C, and alcoholic liver cirrhosis, as evaluated at a single Chinese center.…”

Section: Berberinementioning

confidence: 99%

Dietary Supplements for Cholesterol Management

Almandoz

2015

Contemporary Endocrinology

View full text Add to dashboard Cite

Lipid-lowering effect of berberine in human subjects and rats

Cited by 118 publications

References 28 publications

Effects of Poly-Bioactive Compounds on Lipid Profile and Body Weight in a Moderately Hypercholesterolemic Population with Low Cardiovascular Disease Risk: A Multicenter Randomized Trial

Effects of Poly-Bioactive Compounds on Lipid Profile and Body Weight in a Moderately Hypercholesterolemic Population with Low Cardiovascular Disease Risk: A Multicenter Randomized Trial

A Review on the Traditional Chinese Medicinal Herbs and Formulae with Hypolipidemic Effect

Dietary Supplements for Cholesterol Management

Contact Info

Product

Resources

About